诺和锐30治疗老年初发2型糖尿病的疗效观察

Efficacy of novomix 30 in the treatment of the old patients with type 2 diabetes

目的观察双时相门冬胰岛素30(诺和锐30)治疗老年初发2型糖尿病的疗效,为提高患者生存质量,降低并发症提供依据。方法以我院2010年3月至2012年6月收治的132例初发老年2型糖尿病患者为研究对象,比较使用诺和锐30治疗前后空腹血糖、餐后2 h血糖、糖化血红蛋白、总胆固醇、甘油三脂和体重指数,同时计算治疗前后HOMA-IR和HOMA-β。结果治疗12周后空腹血糖为(5.91±0.96)mmol/L、餐后2 h血糖为(7.81±1.83)mmol/L、糖化血红蛋白为(5.80±0.63)%,与治疗前比较明显下降,差异有统计学意义(P<0.05);治疗前后总胆固醇和甘油三脂均有改善,差异有统计学意义(P<0.05),但治疗前后体重指数差异无统计学意义(P>0.05);治疗后HOMA-IR与治疗前比较胰岛素抵抗有改善(P<0.05),HOMA-β与治疗前比较胰岛敏感性增加(P<0.05);出现两例低血糖,均予高糖饮食后改善,无夜间低血糖发作。结论双时相门冬胰岛素30(诺和锐30)治疗老年初发2型糖尿病安全有效,有利于血糖长期良好控制,值得临床推广。

Objective To observe the efficacy of novomix 30 in the treatment of the old patients with type 2 diabetes, and to improve the survival quality and reduce mortality. Methods A total of 132 old patients with type 2 diabetes from March 2010 to June 2012 were enrolled into this study. Before and after treatment, the fasting blood glu- cose, post-prandial glycemia after 2 hours, glycosylated hemoglobin, total cholesterol, triglyceride and body mass in- dex were compared. HOMA-IR and HOMA-β were calculated. Results After the 12 weeks of treatment, the fasting blood glucose was （5.91±0.96）mmol/L, post-prandial glycemia after 2 hours was （7.81±1.83）mmol/L and glycosylat- ed hemoglobin was （5.80±0.63）%, with significant difference compared with those before treatment （P〈0.05）. The to- tal cholesterol and triglyceride had significant difference （P〈0.05）, but body mass index had no significant difference. Compared with that before treatment, the resistance improved by HOMA-IR （P〈0.05）, the sensitivity of insulin in- creased by HOMA-β after treatment （P〈0.05）. There were two cases with low blood sugar, and improved after high-sugar diet, with no nocturnal hypoglycemia. Condusion Novomix 30 is effective and safe in the treatment for the old patients with type 2 diabetes.